US health regulators remove safety warnings from menopause hormone patches

Regulators removed strict health warnings from menopause patches, reviving interest in hormone therapy.

Health regulators dropped severe safety warnings regarding cardiovascular disease, breast cancer, and dementia from three estrogen patches used to treat menopause. The policy change marks the first major guidance update in over a decade for the hormone therapy. Medical professionals note the decision revived interest in the treatment despite transparency concerns from some specialists.

• The decisionRegulatory officials eliminated black-box warnings on three separate estrogen patches.
• Previous guidanceThe advisory framework remained unchanged for twelve years prior to this update.
• Expert reactionCertain specialists raised transparency concerns over bypassing advisory committees during the policy change.